Multiplexed immune profiling and 3D co-culture assays to assess the individual checkpoint therapy response in head and neck squamous cell carcinoma
BackgroundImmune checkpoint inhibitors (ICIs) have become an integral part of cancer therapy, but only a minority of patients experience durable responsiveness. Response rates vary greatly and are often unpredictable, highlighting the urgent need for predictive biomarkers to guide treatment decision...
Saved in:
| Main Authors: | Verena Schweihofer, Daniela Schulz, Raquel Blazquez, Gero Brockhoff, Tobias Ettl, Mathias Fiedler, Sina Heimer, Juliane Schikora, Richard J. Bauer, Anja Kathrin Wege |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1622008/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapy
by: Verena Schweihofer, et al.
Published: (2025-03-01) -
Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition
by: Alina Goerg, et al.
Published: (2025-06-01) -
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
by: Jing Wei, et al.
Published: (2024-12-01) -
Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC)
by: Ahmed M. Mousa, et al.
Published: (2024-09-01) -
Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment
by: Xiaoye Shi, et al.
Published: (2024-12-01)